Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Trivalency of a Nanobody Specific for the Human Respiratory Syncytial Virus Fusion Glycoprotein Drastically Enhances Virus Neutralization and Impacts Escape Mutant Selection.

Palomo C, Mas V, Detalle L, Depla E, Cano O, Vázquez M, Stortelers C, Melero JA.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6498-6509. doi: 10.1128/AAC.00842-16. Print 2016 Nov.

2.

High Throughput Combinatorial Formatting of PcrV Nanobodies for Efficient Potency Improvement.

De Tavernier E, Detalle L, Morizzo E, Roobrouck A, De Taeye S, Rieger M, Verhaeghe T, Correia A, Van Hegelsom R, Figueirido R, Noens J, Steffensen S, Stöhr T, Van de Velde W, Depla E, Dombrecht B.

J Biol Chem. 2016 Jul 15;291(29):15243-55. doi: 10.1074/jbc.M115.684241. Epub 2016 May 20.

3.

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection.

Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, Millar A, Power UF, Stortelers C, Allosery K, Melero JA, Depla E.

Antimicrob Agents Chemother. 2015 Oct 5;60(1):6-13. doi: 10.1128/AAC.01802-15. Print 2016 Jan.

4.

Nanobodies®: new ammunition to battle viruses.

Vanlandschoot P, Stortelers C, Beirnaert E, Ibañez LI, Schepens B, Depla E, Saelens X.

Antiviral Res. 2011 Dec;92(3):389-407. doi: 10.1016/j.antiviral.2011.09.002. Epub 2011 Sep 10. Review.

PMID:
21939690
5.

Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies.

Verstrepen BE, Depla E, Rollier CS, Mares G, Drexhage JA, Priem S, Verschoor EJ, Koopman G, Granier C, Dreux M, Cosset FL, Maertens G, Heeney JL.

J Infect Dis. 2011 Sep 15;204(6):837-44. doi: 10.1093/infdis/jir423.

6.

Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion.

Haberstroh A, Schnober EK, Zeisel MB, Carolla P, Barth H, Blum HE, Cosset FL, Koutsoudakis G, Bartenschlager R, Union A, Depla E, Owsianka A, Patel AH, Schuster C, Stoll-Keller F, Doffoël M, Dreux M, Baumert TF.

Gastroenterology. 2008 Nov;135(5):1719-1728.e1. doi: 10.1053/j.gastro.2008.07.018. Epub 2008 Jul 22.

PMID:
18718838
7.

Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus.

Meunier JC, Russell RS, Goossens V, Priem S, Walter H, Depla E, Union A, Faulk KN, Bukh J, Emerson SU, Purcell RH.

J Virol. 2008 Jan;82(2):966-73. Epub 2007 Oct 31.

8.

Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections.

Depla E, Van der Aa A, Livingston BD, Crimi C, Allosery K, De Brabandere V, Krakover J, Murthy S, Huang M, Power S, Babé L, Dahlberg C, McKinney D, Sette A, Southwood S, Philip R, Newman MJ, Meheus L.

J Virol. 2008 Jan;82(1):435-50. Epub 2007 Oct 17.

9.

Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction.

Barth H, Schnober EK, Zhang F, Linhardt RJ, Depla E, Boson B, Cosset FL, Patel AH, Blum HE, Baumert TF.

J Virol. 2006 Nov;80(21):10579-90. Epub 2006 Aug 23.

10.

Host cell responses induced by hepatitis C virus binding.

Fang X, Zeisel MB, Wilpert J, Gissler B, Thimme R, Kreutz C, Maiwald T, Timmer J, Kern WV, Donauer J, Geyer M, Walz G, Depla E, von Weizsäcker F, Blum HE, Baumert TF.

Hepatology. 2006 Jun;43(6):1326-36.

11.

Humoral immune response in acute hepatitis C virus infection.

Netski DM, Mosbruger T, Depla E, Maertens G, Ray SC, Hamilton RG, Roundtree S, Thomas DL, McKeating J, Cox A.

Clin Infect Dis. 2005 Sep 1;41(5):667-75. Epub 2005 Jul 22.

PMID:
16080089
12.

Uptake and presentation of hepatitis C virus-like particles by human dendritic cells.

Barth H, Ulsenheimer A, Pape GR, Diepolder HM, Hoffmann M, Neumann-Haefelin C, Thimme R, Henneke P, Klein R, Paranhos-Baccalà G, Depla E, Liang TJ, Blum HE, Baumert TF.

Blood. 2005 May 1;105(9):3605-14. Epub 2005 Jan 18.

PMID:
15657184
13.

Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C.

Steinmann D, Barth H, Gissler B, Schürmann P, Adah MI, Gerlach JT, Pape GR, Depla E, Jacobs D, Maertens G, Patel AH, Inchauspé G, Liang TJ, Blum HE, Baumert TF.

J Virol. 2004 Sep;78(17):9030-40.

14.

A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers.

Leroux-Roels G, Depla E, Hulstaert F, Tobback L, Dincq S, Desmet J, Desombere I, Maertens G.

Vaccine. 2004 Aug 13;22(23-24):3080-6.

PMID:
15297058
15.

Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation.

Ludwig IS, Lekkerkerker AN, Depla E, Bosman F, Musters RJ, Depraetere S, van Kooyk Y, Geijtenbeek TB.

J Virol. 2004 Aug;78(15):8322-32.

16.

Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response.

Rollier C, Depla E, Drexhage JA, Verschoor EJ, Verstrepen BE, Fatmi A, Brinster C, Fournillier A, Whelan JA, Whelan M, Jacobs D, Maertens G, Inchauspé G, Heeney JL.

J Virol. 2004 Jan;78(1):187-96.

17.

A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C.

Nevens F, Roskams T, Van Vlierberghe H, Horsmans Y, Sprengers D, Elewaut A, Desmet V, Leroux-Roels G, Quinaux E, Depla E, Dincq S, Vander Stichele C, Maertens G, Hulstaert F.

Hepatology. 2003 Nov;38(5):1289-96.

PMID:
14578869
18.

Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate.

Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, Kinoshita-Toyoda A, Toida T, Van Kuppevelt TH, Depla E, Von Weizsacker F, Blum HE, Baumert TF.

J Biol Chem. 2003 Oct 17;278(42):41003-12. Epub 2003 Jul 16.

19.

Hepatic immunohistochemical staining with a monoclonal antibody against HCV-E2 to evaluate antiviral therapy and reinfection of liver grafts in hepatitis C viral infection.

Verslype C, Nevens F, Sinelli N, Clarysse C, Pirenne J, Depla E, Maertens G, van Pelt J, Desmet V, Fevery J, Roskams T.

J Hepatol. 2003 Feb;38(2):208-14.

PMID:
12547410
20.

Ultrastructural visualization of hepatitis C virus components in human and primate liver biopsies.

De Vos R, Verslype C, Depla E, Fevery J, Van Damme B, Desmet V, Roskams T.

J Hepatol. 2002 Sep;37(3):370-9.

PMID:
12175633
21.

Detection of neutralizing antibodies to hepatitis C virus using a biliary cell infection model.

Bichr S, Rende-Fournier R, Vona G, Yamamoto AM, Depla E, Maertens G, Bréchot C.

J Gen Virol. 2002 Jul;83(Pt 7):1673-1678. doi: 10.1099/0022-1317-83-7-1673.

PMID:
12075086
22.

Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines.

Wellnitz S, Klumpp B, Barth H, Ito S, Depla E, Dubuisson J, Blum HE, Baumert TF.

J Virol. 2002 Feb;76(3):1181-93.

23.

Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites.

Fournillier A, Wychowski C, Boucreux D, Baumert TF, Meunier JC, Jacobs D, Muguet S, Depla E, Inchauspé G.

J Virol. 2001 Dec;75(24):12088-97.

24.

Interaction of viruses with annexins: a potential therapeutic target?

Depla E.

Curr Opin Investig Drugs. 2000 Dec;1(4):415-20. Review.

PMID:
11249692
25.

Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens.

Vidalin O, Fournillier A, Renard N, Chen M, Depla E, Boucreux D, Brinster C, Baumert T, Nakano I, Fukuda Y, Liljeström P, Trépo C, Inchauspé G.

Virology. 2000 Oct 25;276(2):259-70.

26.

Improvement of chronic active hepatitis C in chronically infected chimpanzees after therapeutic vaccination with the HCV E1 protein.

Maertens G, Priem S, Ducatteeuw A, Verschoorl E, Verstrepen B, Roskams T, Desmet V, Fuller S, Van Hoek K, Vandeponseele P, Bosman F, Buyse MA, van Doorn LJ, Heeney J, Kos A, Depla E.

Acta Gastroenterol Belg. 2000 Apr-Jun;63(2):203. No abstract available.

PMID:
11023431
27.

Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C.

Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, Manns MP, Rehermann B.

Nat Med. 2000 May;6(5):578-82.

PMID:
10802716
28.

Influence of the administration of human annexin V on in vitro binding of small hepatitis B surface antigen to human and to rat hepatocytes and on in vitro hepatitis B virus infection.

De Meyer S, Gong ZJ, Hertogs K, Depla E, van Pelt JF, Roskams T, Maertens G, Yap SH.

J Viral Hepat. 2000 Mar;7(2):104-14.

PMID:
10760040
29.
30.

Characterization of small hepatitis B surface antigen epitopes involved in binding to human annexin V.

De Meyer S, Depla E, Maertens G, Soumillion A, Yap SH.

J Viral Hepat. 1999 Jul;6(4):277-85.

PMID:
10607242
31.
32.
33.

Transfection of a rat hepatoma cell line with a construct expressing human liver annexin V confers susceptibility to hepatitis B virus infection.

Gong ZJ, De Meyer S, van Pelt J, Hertogs K, Depla E, Soumillion A, Fevery J, Yap SH.

Hepatology. 1999 Feb;29(2):576-84.

PMID:
9918938
34.

Modulation of immune responses to hepatitis C virus envelope E2 protein following injection of plasmid DNA using single or combined delivery routes.

Fournillier A, Nakano I, Vitvitski L, Depla E, Vidalin O, Maertens G, Trépo C, Inchauspé G.

Hepatology. 1998 Jul;28(1):237-44.

PMID:
9657118
36.

Desmin expressing nonhematopoietic liver cells during rat liver development: an immunohistochemical and morphometric study.

Kiassov AP, Van Eyken P, van Pelt JF, Depla E, Fevery J, Desmet VJ, Yap SH.

Differentiation. 1995 Nov;59(4):253-8.

PMID:
8575647
37.

Parathyroid hormone-related peptide is expressed and rapidly inducible in human liver cell cultures that have a bile duct phenotype.

Roskams T, Moshage H, Depla E, Willems M, Desmet V, Yap P.

J Hepatol. 1995 Aug;23(2):160-5.

PMID:
7499787
38.

Hepatitis B virus: specific binding and internalization of small HBsAg by human hepatocytes.

de Bruin WC, Hertogs K, Leenders WP, Depla E, Yap SH.

J Gen Virol. 1995 Apr;76 ( Pt 4):1047-50.

PMID:
9049356
40.

Hepatitis delta virus attaches to human hepatocytes via human liver endonexin II, a specific HBsAg binding protein.

de Bruin W, Leenders W, Kos T, Hertogs K, Depla E, Yap SH.

J Viral Hepat. 1994;1(1):33-8.

PMID:
8790557
41.

Endonexin II, present on human liver plasma membranes, is a specific binding protein of small hepatitis B virus (HBV) envelope protein.

Hertogs K, Leenders WP, Depla E, De Bruin WC, Meheus L, Raymackers J, Moshage H, Yap SH.

Virology. 1993 Dec;197(2):549-57.

PMID:
8249278
42.
43.

Expression of interferon-gamma receptor in normal and pathological human liver tissue.

Volpes R, van den Oord JJ, De Vos R, Depla E, De Ley M, Desmet VJ.

J Hepatol. 1991 Mar;12(2):195-202.

PMID:
1828821
44.

Monoclonal antibodies against the human interferon-gamma receptor(s).

Depla E, De Ley M.

Mol Immunol. 1990 Aug;27(8):745-50.

PMID:
2144891

Supplemental Content

Support Center